Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ionis Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Ionis Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
LTS:0JDI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.69 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Ionis Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
LTS:0JDI vs EXEL, BBIO, AXSM: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Ionis Pharmaceuticals (LTS:0JDI) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 20, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ionis Pharmaceuticals and its competitors. According to the industry distribution chart, Ionis Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry.
Is Ionis Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Ionis Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Ionis Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ionis Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' 5-Year Yield-on-Cost % compare to EXEL and BBIO?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Ionis Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.69, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Fairly Valued. The stock's GF Value™ is $53.51, compared to a current price of $53.97 — trading 0.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Ionis Pharmaceuticals' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of $53.97 is trading 0.9% above its estimated GF Value™ of $53.51.
GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0JDI:
5-Year Yield-on-Cost %: 0.00
GF Value™: $53.51 vs. price of $53.97 (0.9% above fair value)
No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
66GF Score
Get the complete analysis for LTS:0JDI
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDI has been successfully added to your 
